• Japanese
  • Korean
  • Chinese
Cover Image

Parkinson's Disease: World Drug Industry and Market 2014-2024

Treating Parkinson's - how you find business trends, R&D, and revenue forecasts

See the future of Parkinson's drugs. For those treatments you can get new sales predictions, also exploring research and development. You unlock that CNS medical industry. And you assess its results, trends, technologies, therapies, and opportunities.

Visiongain's report forecasts those revenues to 2024 at overall world market, submarket, product, and national level. You stay ahead in data, then, finding commercial prospects. And you hear about gains for companies, doctors, and patients, also benefiting your influence.

So read on to investigate those medicines and see what their future could be worth.

Sales predictions to 2024 and other analyses show you commercial prospects

Besides forecasting revenues to 2024, our study gives you recent results, growth rates, and market shares. There you find original analysis, with business outlooks and developments (R&D). Also you get 68 tables, 47 charts, and interviews with two companies.

There you discover the most lucrative opportunities for treating that central nervous system (CNS) disorder. You find where the money lies, exploring existing and potential sales.

Knowledge to help your work on that degenerative disorder

Ever found business data hard to find? Instead see how our report helps your research, analyses, and decisions for treatment of Parkinson's disease (PD). Save time too, and stay ahead. Also benefit your authority through better understanding the present and future.

Avoid missing out. And the following sections explain what you get in that new investigation.

Forecasting of that world market and its segments - you explore possibilities

What're the secrets of that industry's progress? Where lies potential in alleviating symptoms and treating PD? Discover in our report overall world revenue to 2024 for those central nervous system (CNS) medicines.

Also find individual revenue predictions to 2024 for five therapeutic submarkets at world level:

  • Dopaminergic agents
  • Dopamine receptor agonists
  • COMT inhibitors
  • MAO inhibitors
  • Treatments with other modes of action (grouped).

There you assess outlooks for sales growth, seeing where you can gain.

Like to know what happens next? You explore competition and rising sales for products, including biological drugs (biologics). You get feel for that sector and its potential.

So discover the sales possibilities there. See, too, how patients benefit. And you find top products' potentials.

Predictions of revenues for leading Parkinson's drugs

Find sales outlooks for brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for three leading products:

  • Comtan and Stalevo
  • Azilect
  • Neupro.

There you find products and years with highest predicted revenues and growth. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and sales potentials. Discover where you could profit.

Our work also divides its overall predictions into geographical regions.

Healthcare in leading national markets - what outlooks for those medical sales?

In developed and developing countries, opportunities for selling products treating Parkinson's disease will improve from 2014 to 2024. See where and how, finding commercial potentials of therapeutic agents for that neurodegenerative disorder.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:

  • United States (US)
  • Japan
  • EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
  • BRIC nations - Brazil, Russia, India, and China.

There you find countries with highest revenues, demand, and potential sales growth. Our work explains. You assess needs and demands for that specialist medicine.

Explore, too, how that biomedical and biopharma technology benefits developers, producers, marketers, and sellers tackling that neurological disease.

Also, what events change that market? Our work shows you, discussing trends and needs.

Events and forces for developing, producing, marketing, and selling PD medicines

Our report shows you issues and events affecting that biomedical and pharma segment from 2014, including these:

  • R&D for Parkinson's (idiopathic or primary parkinsonism, hypokinetic rigid syndrome/HRS, or paralysis agitans), including stem cells and gene therapy
  • Levodopa therapy, its reformulations, and patient expiry - rising competition
  • Demographic trends worldwide affecting treatment needs and demand for PD drugs
  • Economic changes stimulating sales of those medical agents
  • Neuroprotective medicines (neuroprotection) giving hope.

So you explore political, economic, social, and technological questions for treating Parkinson's, investigating outlooks for commerce. See too how R&D can let companies benefit patients. Discover what the future holds.

You find, then, what stimulates and restrains players in that sector, and affects its results.

Companies and 2018 market value - find prospects for success in PD medicines

What happens next? Our new study predicts the world market for Parkinson's-treating drugs will reach $3461m in 2018. There big pharma and specialty companies can gain, expanding business. Explore how and where.

And there you examine activities of many organisations, including these firms:

  • Orion Pharmaceuticals
  • Novartis
  • Boehringer Ingelheim
  • GlaxoSmithKline (GSK)
  • Teva Pharmaceutical Industries.

R&D for treating PD holds advantages, and from 2014 there will arise opportunity. From this decade, patients, payers, and producing companies will benefit.

And you discover how that market can perform, staying ahead in data.

Ways Parkinson's Disease: World Drug Industry and Market 2014-2024 helps you

In particular, our investigation gives you this knowledge:

  • Revenues there to 2024 at world level, for 5 submarkets, and 3 top products - assess outlooks for production, marketing, and sales
  • Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues
  • Prospects for established competitors, emerging companies, and new entrants - explore portfolios, results, strategies, successes, and developmental activities.

Table of Contents

1. Executive Summary

  • 1.1 Parkinson's Disease Therapy: World Market Overview to 2024
  • 1.2 Chapter Outlines
  • 1.3 Research and Analysis Methods

2. Introduction to Parkinson's Disease and its Treatments

  • 2.1 What Causes Parkinson's?
  • 2.2 Motor Symptoms of Parkinson's Disease
    • 2.2.1 Tremor: The First Sign of PD
    • 2.2.2 Uncontrolled Muscle Contractions Cause Rigidity
    • 2.2.3 Bradykinesia: The Most Characteristic Feature of Parkinson's
    • 2.2.4 Postural Instability Manifests as PD Progresses
  • 2.3 Neuropsychiatric Symptoms are Common in PD Patients
    • 2.3.1 Behavioural Deficits are Often the Most Widespread
    • 2.3.2 Cognitive Impairment Impede Daily Tasks
    • 2.3.3 Autonomic Dysfunction: Another Common Occurrence
  • 2.4 Other Symptoms Associated with Parkinson's
  • 2.5 Parkinson's Disease: Diagnosis and Treatment
    • 2.5.1 Diagnosis is Difficult
    • 2.5.2 Treatment Options - Therapeutic Classes

3. Parkinson's Disease: World Drugs Market, 2014-2024

  • 3.1 Sales of the Overall World PD Drugs Market, 2013-2024
  • 3.2 Parkinson's Disease: Market Segmentation, 2012
  • 3.3 Overall PD Drug Market: Commercial Drivers and Restraints
  • 3.4 Dopaminergic Agents: Foundation of PD Treatment
    • 3.4.1 Levodopa Therapy
    • 3.4.2 Patent Expiries Affect the Market
    • 3.4.3 New Levodopa Therapies on the Horizon
    • 3.4.4 Dopaminergic Agents: Market Projections to 2024
  • 3.5 Dopamine Receptor Agonists: The Leading Class in 2013
    • 3.5.1 Dopamine Agonists: A Front Line Drug
    • 3.5.2 Advantages over L-Dopa Therapy
    • 3.5.3 Leading Drugs in the Segment
    • 3.5.4 Thin R&D Pipeline in That Segment
    • 3.5.5 Dopamine Receptor Agonists: Market Projections, 2014-2024
  • 3.6 Catechol-O-Methyl Transferase (COMT) Inhibitors: A Popular Choice of Treatment
    • 3.6.1 Entacapone: The Leading Drug in this Segment
    • 3.6.2 Commercial Scope for COMT Inhibitors
    • 3.6.3 COMT Inhibitors: Market Projections, 2014-2024
  • 3.7 Are Monoamine Oxidase-B (MAO-B) Inhibitors Better Than COMT?
    • 3.7.1 MAO-B Inhibitor Therapeutics in the Market
    • 3.7.2 New MAO-B Products in Development
    • 3.7.3 MAO-B Inhibitors: Market Projections, 2014-2024
    • 3.7.4 Other Mechanisms of Action: A Growing Opportunity
    • 3.7.5 A Broad and Diverse Segment
      • 3.7.5.1 Anticholinergics Therapeutics: The Oldest Class of PD Drugs
      • 3.7.5.2 Glutamate Antagonists: Not a Popular Choice
    • 3.7.6 Other Drugs in the Market
    • 3.7.7 The Pipeline Offers Disease Modifying Potential
    • 3.7.8 Other Mechanisms of Action: Market Projections, 2014-2024

4. Leading Companies in the PD Drug Market, 2014

  • 4.1 PD: The Most Important Therapy Area for Orion Pharmaceuticals
    • 4.1.1 Market Forecast for Comtan/Stalevo, 2014-2024
  • 4.2 Teva's Azilect Continues to Grow
    • 4.2.1 Market Forecast for Azilect, 2014-2024
  • 4.3 UCB's Leading Neupro Patch Drug
    • 4.3.1 Market Forecast for Neupro, 2014-2024
  • 4.4 Other Market Players

5. The Leading National Markets, 2014-2024

  • 5.1 Regional Breakdown of the World PD Drug Market, 2012
  • 5.2 The World PD Drug Market: Regional Forecasts to 2024
  • 5.3 The PD Drug Market in the US: The Largest Single National Market
    • 5.3.1 Market Projections for the US, 2014-2024
  • 5.4 The PD Drug Market in the Five Leading European National Markets (EU5), 2014-2024
    • 5.4.1 Market Projections for the EU5, 2014-2024
    • 5.4.2 EU5 Breakdown by Country, 2012
    • 5.4.3 Market Projection for EU5 Countries, Regional Breakdown
    • 5.4.4 Germany: The Largest EU5 Market
      • 5.4.4.1 Predictions for the German PD Drug Market, 2014-2024
    • 5.4.5 France: Strong Healthcare System - What's Possible There?
      • 5.4.5.1 Predictions for the French PD Drug Market, 2014-2024
    • 5.4.6 UK's Spending Restrictions Affect the PD Drugs Market
      • 5.4.6.1 Predictions for the UK PD Drug Market, 2014-2024
    • 5.4.7 Spain - What Effects Will Austerity Have on PD Drug Sales?
      • 5.4.7.1 Predictions for the Spanish PD Drug Market, 2014-2024
    • 5.4.8 The PD Drug Market in Italy: Rising Ageing Population
      • 5.4.8.1 Predictions for the Italian PD Drug Market, 2014-2024
  • 5.5 Japan has the Highest Proportion of Over-65s in the World
    • 5.5.1 Predictions for Japanese PD Drug Market, 2014-2024
  • 5.6 PD Drug Market in Emerging Countries: Brazil, Russia, India and China (BRIC)
    • 5.6.1 Breakdown of BRIC Revenues by Country, 2012
    • 5.6.2 Market Projections for BRIC Nations' PD Drug Sales, 2014-2024
    • 5.6.3 Brazil's Rapid Growth of the Pharma Market - What's the Future?
    • 5.6.4 Russia's Growing Middle-Class Gives Pharma Sales Opportunities
    • 5.6.5 India: Generic Manufacturers Seek to Dominate the PD Market
    • 5.6.6 China's Ageing Population Stimulates Sales of PD-Treating Medicines

6. Research and Development for Treating Parkinson's Disease

  • 6.1 New Mechanisms of Action in the Late-Stage R&D Pipeline
  • 6.2 Growing Potential of Marketed Products: Phase IV Studies
  • 6.3 Phase III Clinical Products Promising Potential in the PD market
    • 6.3.1 Rytary (Impax Laboratories): The New Generation of Levodopa
      • 6.3.1.1 Reformulations of Levodopa: Important Aspect of Therapy
    • 6.3.2 Newron's Safinamide Expected Launch in 2014
    • 6.3.3 Pimavanserin: A First-in-Class Treatment for Parkinson's Disease Psychosis
    • 6.3.4 Istradefylline: A Promising A(2a) Receptor Antagonist
    • 6.3.5 Termination of Preladenant, A Promising A(2a) Receptor Antagonist
    • 6.3.6 Levodopa/Carbidopa Intestinal Gel (LCIG)
    • 6.3.7 Can Opicapone Compete with Existing COMT Inhibitors
    • 6.3.8 Pitolisant: Addressing an Unmet Need
    • 6.3.9 Northera: Oral Precursor of Norepinephrine
    • 6.3.10 Targin by Mundipharm
    • 6.3.11 Nurelin for Levodopa-Induced Dyskinesia
    • 6.3.12 SYN-115: Superior to Istradefylline?
  • 6.4 Phase II PD Pipeline: Overview
    • 6.4.1 Glutamatergic Drugs: Main Target for Pipeline Candidates
      • 6.4.1.1 AFQ056 vs Dipraglurant
    • 6.4.2 Fipamezole: Another Promising A(2a) Receptor Antagonist
    • 6.4.3 CVT-301: A Novel Intrapulmonary Approach
    • 6.4.4 DM-1992: Can Compete with Levodopa Reformulations?
    • 6.4.5 The Accordion Pill Carbidopa/Levodopa by Intec Pharma
    • 6.4.6 Orient Addresses Sialorrhoea
    • 6.4.7 NH004: Formulated with a Muco-Adhesive Property
    • 6.4.8 VR040: A Reformulation of Apomorphine
    • 6.4.9 AVP-923: A Novel Approach for LID-PD
    • 6.4.10 PD Giant Orion, Develop a New Levodopa Drug, ODM-101
    • 6.4.11 News for NeuroDerm's Reformulations
  • 6.5 Phase I and Pre-clinical PD Pipeline: Overview
    • 6.5.1 Vernalis' A(2a) Receptor Antagonist Drug in Phase Ib/IIa
    • 6.5.2 Sanofi Collaborates with The Michael J. Fox Foundation
    • 6.5.3 UCL Show Exenatide Potential in Parkinson's
    • 6.5.4 Titan Pharmaceuticals Develop a Novel Platform
  • 6.6 Neuroprotective Drugs Offer Hope
    • 6.6.1 Isradipine by The Parkinson Study Group
    • 6.6.2 Phytopharm and Cogane Development
    • 6.6.3 The Potential of Dietary Supplements
    • 6.6.4 GCase Enzymes: Amicus and Biogen Strike A Deal for Parkinson's
    • 6.6.5 Research Finds Ursodeoxycholic Acid (UDCA) A Potential Cure for Parkinson's
    • 6.6.6 PD Biomarkers: Potential for Revolutionising Diagnosis and Treatment
    • 6.6.7 Antibody Targeting: The Coming of Age
  • 6.7 Gene Therapy: Promising Research and Technology
    • 6.7.1 ProSavin: Leading Gene Therapy Product
    • 6.7.2 CERE-120 Promises Repair of Damaged Dopaminergic Neurons
    • 6.7.3 AAV-hAADC-2: Another Gene Therapy Contender
    • 6.8 Parthenogenesis (International Stem Cell Corporation): A Promising Outlook for PD Technology

7. Qualitative Analysis of the PD Drug Market, 2014

  • 7.1 SWOT Analysis of the PD Market
    • 7.1.1 Strengths and Weaknesses in the PD Drug Industry in 2014
    • 7.1.2 Opportunities and Threats There from 2014 Onwards
  • 7.2 STEP Analysis of the PD Market
    • 7.2.1 Social Implication of Living with PD
    • 7.2.2 Technological Developments on the Horizon
    • 7.2.3 Economic Pressures: Healthcare Budgeting
    • 7.2.4 Political Issues: Patent Challenges, Data Exclusivity and Regulatory Pathways

8. Research Interviews

  • 8.1 Interview with Dr. Simon Craw, International Stem Cell Corporation, California, US
    • 8.1.1 The Overall PD Market
    • 8.1.2 Current Understanding of Stem Cell Therapy
    • 8.1.3 ISCO's Novel PD Programme
    • 8.1.4 The Potential of Immune-Matching
    • 8.1.5 The Controversy Surrounding Stem Cell Research
    • 8.1.6 The Potential for Parthenogenesis in PD and Other Applications
  • 8.2 Interview with Dr Neal Farber, CEO, NeuroHealing Pharmaceuticals, Massachusetts, US
    • 8.2.1 Advantages of Anticholinergics over Current Treatment Methods
    • 8.2.2 Application of NH004 in Other Neurological Diseases
    • 8.2.3 Improving Quality of Life

9. Conclusions from the Research and Analysis

  • 9.1 The World PD Medicines Market: Predictions to 2024
  • 9.2 Which Drug Class will Dominate the Market in 2024?
  • 9.3 Disease Modification: The Ultimate Goal
  • 9.4 The Future of the Industry and Market for Parkinson's Medicines

List of Tables

  • Table 2.1 Overview of the Therapeutic Drug Classes for PD, 2014
  • Table 3.1 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2013-2018
  • Table 3.2 World Parkinson's Disease Drug Market, Revenue ($m), AGR (%), CAGR (%), 2019-2024
  • Table 3.3 PD Market Segmentation, Revenues ($m), Market Shares (%), 2012
  • Table 3.4 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.5 PD Market Breakdown by Segment: Forecasts ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 3.6 Formulations of Levodopa Therapy, 2013
  • Table 3.7 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.8 Dopaminergic Agents Segment Forecast: Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 3.9 Overview of Therapeutic Drug Classes in PD Therapy, 2014
  • Table 3.10 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.11 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 3.12 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.13 COMT Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 3.14 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.15 MAO Inhibitors Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 3.16 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 3.17 Other Mechanisms of Action Segment Forecast, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 4.1 Orion's Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018
  • Table 4.2 Orion's Comtan/Stalevo Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.3 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018
  • Table 4.4 Teva's Azilect Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 4.5 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2018
  • Table 4.6 UCB's Neupro Forecast: Revenues ($m), AGR (%), CAGR (%), 2019-2024
  • Table 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012
  • Table 5.2 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.3 PD Market Breakdown by Region, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.4 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.5 US PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.6 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.7 EU5 PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.8 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012
  • Table 5.9 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.10 EU5 Regional Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.11 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.12 German PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.13 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.14 French PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.15 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.16 UK PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.17 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.18 Spanish PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.19 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.20 Italian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.21 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.22 Japanese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.23 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.24 BRIC PD Drug Market Revenue ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.25 BRIC Regional Breakdown by Country, Revenues ($m), Market Shares (%), 2012
  • Table 5.26 BRIC PD Drug Market Breakdown by Country, Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.27 BRIC PD Drug Market Breakdown Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.28 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.29 Brazilian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.30 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.31 Russian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.32 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.33 Indian PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 5.34 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2013-2018
  • Table 5.35 Chinese PD Drug Market Revenues ($m), AGR (%), CAGR (%), Market Share (%), 2019-2024
  • Table 6.1 Late-Stage PD Pipeline, 2013
  • Table 6.2 Reformulations of Levodopa and Other Dopaminergic Agents in Development, 2013
  • Table 6.3 Phase II PD Pipeline, 2013
  • Table 6.4 Glutamatergic PD Pipeline, 2013
  • Table 6.5 Early-Stage Developments for PD, 2013
  • Table 6.6 Selected Gene Therapies in the PD Pipeline, 2013
  • Table 7.1 Parkinson's Disease Drug Market: Strengths and Weaknesses, 2014
  • Table 7.2 Parkinson's Disease Drug Market: Opportunities and Threats, 2014-2024
  • Table 7.3 PD Drug Market: STEP Analysis, 2014

List of Figures

  • Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024
  • Figure 3.1 World PD Drug Market, Revenues ($m), 2012-2024
  • Figure 3.2 PD Market Segmentation ($m), Market Shares (%), 2012
  • Figure 3.3 PD Drug Market Breakdown by Segment, Revenues ($m), 2013-2024
  • Figure 3.4 PD Drug Market, Drivers and Restraints, 2014-2024
  • Figure 3.5 Dopaminergic Agents Segment Forecast, Revenues ($m), 2013-2024
  • Figure 3.6 Dopaminergic Agents Market: Drivers and Restraints, 2014-2024
  • Figure 3.7 Dopamine Receptor Agonists Segment Forecast, Revenues ($m), 2013-2024
  • Figure 3.8 Dopamine Receptor Agonists Market, Drivers and Restraints, 2014-2024
  • Figure 3.9 COMT Inhibitors Segment Forecast, Revenues ($m), 2013-2024
  • Figure 3.10 COMT Inhibitors Market, Drivers and Restraints, 2014-2024
  • Figure 3.11 MAO Inhibitors Segment Forecast, Revenues ($m), 2013-2024
  • Figure 3.12 MAO Inhibitors Market, Drivers and Restraints, 2014-2024
  • Figure 3.13 Other Mechanisms of Action Segment Forecast, Revenues ($m), 2013-2024
  • Figure 3.14 Other Mechanisms of Action, Market Drivers and Restraints, 2014-2024
  • Figure 4.1 Revenues ($m) of Parkinson's Drugs by Leading Company, 2010-2012
  • Figure 4.2 Orion's Comtan/Stalevo Drug Revenues ($m) Forecast, 2013-2024
  • Figure 4.3 Teva's Azilect Drug Revenues Forecast, 2013-2024
  • Figure 4.4 UCB's Neupro Drug Revenues Forecast, 2013-2024
  • Figure 5.1 PD Market Breakdown by Region, Revenues ($m), Market Shares (%), 2012
  • Figure 5.2 PD Drug Market Breakdown by Region, Revenues ($m), 2013-2024
  • Figure 5.3 US Over-65 Population as Percentage of Overall Population, 2012-2024
  • Figure 5.4 US PD Drug Market, Revenue Forecast ($m), 2013-2024
  • Figure 5.5 EU5 PD Drug Market, Revenue ($m), 2013-2024
  • Figure 5.6 EU5 Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012
  • Figure 5.7 EU5 Regional Breakdown by Country, Revenues ($m), 2013-2024
  • Figure 5.8 Over-65 Population in Germany as Percentage of Overall Population, 2012-2024
  • Figure 5.9 German PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.10 Over-65 Population in France as Percentage of Overall Population, 2012-2024
  • Figure 5.11 French PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.12 Over-65 Population in the UK as a Percentage of Overall Population, 2013-2024
  • Figure 5.13 UK PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.14 Over-65 Population in Spain as Percentage of Overall Population, 2012-2024
  • Figure 5.15 Spanish PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.16 Over-65 Population in Italy as Percentage of Overall Population, 2012-2024
  • Figure 5.17 Italian PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.18: Over-65 Population in Japan as Percentage of Overall Population, 2012-2024
  • Figure 5.19 Japanese PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.20 BRIC PD Drug Market, Revenue ($m), 2012-2024
  • Figure 5.21 BRIC Regional Breakdown by Country, Revenues ($m), Market Share (%), 2012
  • Figure 5.22 BRIC PD Drug Market Breakdown, Revenues ($m), 2013-2024
  • Figure 5.23 Brazilian PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.24 Russian PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.25 Indian PD Drug Market, Revenues ($m), 2013-2024
  • Figure 5.26 Chinese PD Drug Market, Revenues ($m), 2013-2024
  • Figure 8.1 Parthenogenesis Results in Cells Inheriting a Duplicate Set of HLA Genes, which Reduces Immune Rejection
  • Figure 9.1 PD Drug Market, Overall Revenues ($m), 2012, 2018 and 2024
  • Figure 9.2 PD Drug Market by Segment, Revenues ($m), 2012, 2018 and 2024

Companies Listed

  • Abbott Laboratories
  • AbbVie Pharmaceuticals
  • Acadia Pharmaceuticals
  • Adamas Pharmaceuticals
  • Addex Therapeutics
  • Amarantus BioSciences
  • American Academy of Neurology
  • Amgen
  • Amicus Therapeutics
  • Amylin Pharmaceuticals
  • Ark Therapeutics
  • Assogenerici
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Axxonis Pharma
  • BIAL - Portela
  • Biogen Idec
  • Bioprojet Pharma
  • BioSante Pharmaceuticals
  • Biotie Therapies
  • Biovail
  • Boehringer Ingelheim
  • Cardiovascular and Renal Drug Advisory Committee
  • Ceregene
  • Chelsea Therapeutics
  • Civitas Therapeutics
  • Columbia University
  • Dainippon Sumitomo Pharma
  • Depomed
  • DiaGenic
  • Domain Therapeutics
  • Dr. Reddy's Laboratories
  • Duke University, Duke Medical Center
  • Durin Technologies
  • Eisai
  • European Medicines Agency (EMEA/EMA)
  • Food and Drug Administration (US FDA)
  • Genzyme
  • GlaxoSmithKline (GSK)
  • Impax Laboratories
  • Intec Pharma
  • International Stem Cell Corporation (ISCO)
  • Ipsen
  • Juvantia Pharma
  • Kyowa Hakko Kirin
  • Lundbeck
  • Meiji Seika
  • Merck & Co.
  • Merck Serono
  • Ministry of Health, Labour and Wealth (MHLW)
  • Mundipharma Research
  • Mylan
  • Napp Pharmaceuticals
  • National Health Service (NHS, UK)
  • National Institute for Health and Clinical Excellence (NICE, UK)
  • National Institute of Neurological Disorders and Stroke (NINDS, US)
  • National Institutes of Health (NIH, US)
  • National Parkinson Foundation
  • Neuren Pharmaceuticals
  • Neuroderm
  • NeuroGeneration
  • NeuroHealing Pharmaceuticals
  • Neurologix
  • New Jersey School of Osteopathic Medicine (UMDNJ-SOM)
  • Newron Pharmaceuticals
  • Novartis
  • NuroPro
  • Ono Pharmaceuticals
  • Orient Pharma
  • Orion
  • Otsuka Pharmaceuticals
  • Oxford BioMedica
  • Par Pharmaceuticals
  • Parkinson's UK
  • Pfizer
  • Pharmaceutical Research and Manufacturers Association (PhRMA)
  • Phytopharm
  • Power3 Medical Products
  • Prothena Corporation
  • Roche
  • Roxane Laboratories
  • Sanofi
  • Santhera
  • Schering Plough
  • Sheffield Institute for Translational Neuroscience (SITraN)
  • SK Biosciences
  • Skyepharma
  • Sun Pharmaceuticals
  • Technion-Israel Institute of Technology
  • Teva Pharmaceutical Industries
  • The Michael J. Fox Foundation
  • The Parkinson Study Group
  • Titan Pharmaceuticals
  • UCB
  • uniQure
  • University College London (UCL)
  • Valeant
  • Varinel
  • Vectura Group
  • Vernalis
  • Watson Pharmaceuticals
  • Wockhardt
  • XenoPort
  • Yale University
  • Zambon Group
Show More
Pricing
Get Notified
Email me when related reports are published